A Phase 2 interventional study of RVT-1401 (Administered via subcutaneous injection) and Placebo (Administered via subcutaneous injection) in Graves' Ophthalmopathy (GO), sponsored by Immunovant Sciences GmbH. Terminated at 25 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-22.
Sponsored by Immunovant Sciences GmbH · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Graves Ophthalmopathy with a site in United States — 12 open to participants now, 18 under way, 8 of them phase 3. Graves Ophthalmopathy · United States.
Among the 53 studies in Graves Ophthalmopathy with a site in United States, this one is the 29th largest by enrollment of the 47 interventional ones that give a count, is the only one that started in 2019, is one of 7 in phase 2, and was the 12th registered.
199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.
Browse Graves Ophthalmopathy studies →12 of the 53 studies in Graves Ophthalmopathy with a site in United States are open now. Recruiting first, the newest first:
Minghui Pharmaceutical (Hangzhou) Ltd · Sites in United States
Ages 18–75
Minghui Pharmaceutical (Hangzhou) Ltd · Sites in United States
Ages 18–75
Sling Therapeutics, Inc. · Sites in United States
Ages 18+
Ethyreal Bio, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
Amgen · Sites in United States, Poland, Spain and 1 more country
Ages 18–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 24 · Phase 4 5
First in 2006; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is close to the median of 63 across 146 interventional studies indexed under Graves Ophthalmopathy.
Median enrollment 84 across the 47 interventional studies, 100 across the 5 observational. Of the 33 that completed or were terminated, 17 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 53 have an industry lead sponsor. The 10 most frequent:
Immunovant Sciences GmbH is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 5 (45%) have results posted.
Immunovant Sciences GmbH has 5 studies filed under Graves Ophthalmopathy — fewer than ten, so there is no comparison to draw.
4 of the studies in Graves Ophthalmopathy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06401044AmgenA Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease | 2027-01-06 |
| NCT07832136Viridian Therapeutics, Inc.An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab | 2027-04 |
| NCT07623837THYROSCOPE INC.Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM) | 2027-06-30 |
| NCT07623993THYROSCOPE INC.Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE) | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 53 studies in Graves Ophthalmopathy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the current study is to assess the efficacy and safety/tolerability of three dose regimens of RVT-1401 in the treatment of active, moderate to severe GO participants. In addition, the study is designed to characterize the effect of RVT-1401 exposure on reduction in anti-TSHR IgG
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Regimen A= RVT-1401 680 mg weekly for 12 weeks
Drug: RVT-1401 (Administered via subcutaneous injection)
Regimen B= RVT-1401 340 mg weekly for 12 weeks
Drug: RVT-1401 (Administered via subcutaneous injection)
Regimen C= RVT-1401 255 mg weekly for 12 weeks
Drug: RVT-1401 (Administered via subcutaneous injection)
for 12 weeks
Other: Placebo (Administered via subcutaneous injection)
RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
Placebo
Percentage of Participants With Proptosis Response at Week 13
Proptosis was assessed using an exophthalmometer. A proptosis response was defined as having at least a 2 millimeter (mm) reduction in study eye proptosis without a deterioration (at least a 2 mm increase) in the fellow eye at the same visit. The study eye was defined as the most severely affected eye at the baseline visit.
Time frame: Baseline; Week 13
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs)
AEs - any untoward medical occurrences in a participant, temporally associated with use of a medicinal product, whether or not considered related to the product. Clinically significant changes determined by the Investigator such as vital signs, ECGs, and clinical laboratory values were also reported as AEs. TEAE is defined as an AE that starts on or after the first dose of the study drug and before 30 days after the last dose of the study drug. SAEs were defined as any untoward medical occurrences that: resulted in death; were life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; were congenital anomaly/birth defects; were important medical events that may have jeopardized the participant or may have required medical or surgical intervention; invasive or malignant cancers; and development of drug dependency or drug abuse.
Time frame: From Baseline up to Week 20
Least Square Mean Percent Change From Baseline in Binding Anti-thyroid-stimulating Hormone Receptor (TSHR) Antibody Levels to Week 13
Binding Anti-TSHR antibody serum levels are directly associated with GO clinical features. Baseline was the last available assessment prior to the time of the first dose unless it was specified otherwise and was identified as Day 1. A negative change from baseline in binding anti-TSHR antibody levels indicated therapeutic benefit.
Time frame: Baseline and Week 13
Least Square Mean Percent Change From Baseline in Total IgG Levels
Blood samples we collected to determine total IgG levels. Baseline was the last available assessment prior to the time of the first dose unless it was specified otherwise and was identified as Day 1. A negative change from baseline in the IgG levels indicated therapeutic benefit.
Time frame: Baseline and Week 13
Least Square Mean Percent Change From Baseline in IgG Subclasses 1, 2, 3 and 4
Blood samples were collected to determine IgG 1,2,3 and 4 levels. Baseline was the last available assessment prior to the time of the first dose unless it was specified otherwise and was identified as Day 1. A negative change from baseline in the IgG levels indicated therapeutic benefit.
Time frame: Baseline and Week 13
| Milestone | RVT-1401 680 mg/Week | RVT-1401 340 mg/Week | RVT-1401 255 mg/Week | Placebo |
|---|---|---|---|---|
| Started | 18 | 19 | 10 | 18 |
| Completed | 10 | 14 | 7 | 13 |
| Not completed | 8 | 5 | 3 | 5 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 1 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 6 | 4 | 2 | 4 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
Proptosis was assessed using an exophthalmometer. A proptosis response was defined as having at least a 2 millimeter (mm) reduction in study eye proptosis without a deterioration (at least a 2 mm increase) in the fellow eye at the same visit. The study eye was defined as the most severely affected eye at the baseline visit.
| Percentage of participants | RVT-1401 680 mg/Week | RVT-1401 340 mg/Week | RVT-1401 255 mg/Week | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Proptosis Response at Week 13 | 30.0 | 30.8 | 0 | 8.3 |
AEs - any untoward medical occurrences in a participant, temporally associated with use of a medicinal product, whether or not considered related to the product. Clinically significant changes determined by the Investigator such as vital signs, ECGs, and clinical laboratory values were also reported as AEs. TEAE is defined as an AE that starts on or after the first dose of the study drug and before 30 days after the last dose of the study drug. SAEs were defined as any untoward medical occurrences that: resulted in death; were life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; were congenital anomaly/birth defects; were important medical events that may have jeopardized the participant or may have required medical or surgical intervention; invasive or malignant cancers; and development of drug dependency or drug abuse.
| Participants | RVT-1401 680 mg/Week | RVT-1401 340 mg/Week | RVT-1401 255 mg/Week | Placebo |
|---|---|---|---|---|
| TEAEs | 16 | 16 | 8 | 16 |
| SAEs | 0 | 0 | 1 | 0 |
Binding Anti-TSHR antibody serum levels are directly associated with GO clinical features. Baseline was the last available assessment prior to the time of the first dose unless it was specified otherwise and was identified as Day 1. A negative change from baseline in binding anti-TSHR antibody levels indicated therapeutic benefit.
| Percent change | RVT-1401 680 mg/Week | RVT-1401 340 mg/Week | RVT-1401 255 mg/Week | Placebo |
|---|---|---|---|---|
| Least Square Mean Percent Change From Baseline in Binding Anti-thyroid-stimulating Hormone Receptor (TSHR) Antibody Levels to Week 13 | -64.605 (-87.006 to -42.205) | -69.663 (-89.272 to -50.054) | -41.843 (-70.070 to -13.616) | -4.520 (-25.580 to 16.539) |
Blood samples we collected to determine total IgG levels. Baseline was the last available assessment prior to the time of the first dose unless it was specified otherwise and was identified as Day 1. A negative change from baseline in the IgG levels indicated therapeutic benefit.
| Percent change | RVT-1401 680 mg/Week | RVT-1401 340 mg/Week | RVT-1401 255 mg/Week | Placebo |
|---|---|---|---|---|
| Least Square Mean Percent Change From Baseline in Total IgG Levels | -79.101 (-86.444 to -71.757) | -65.103 (-71.687 to -58.519) | -57.934 (-67.216 to -48.651) | -6.098 (-12.948 to 0.753) |
Blood samples were collected to determine IgG 1,2,3 and 4 levels. Baseline was the last available assessment prior to the time of the first dose unless it was specified otherwise and was identified as Day 1. A negative change from baseline in the IgG levels indicated therapeutic benefit.
| Percent change | RVT-1401 680 mg/Week | RVT-1401 340 mg/Week | RVT-1401 255 mg/Week | Placebo |
|---|---|---|---|---|
| IgG1 | -82.040 (-90.757 to -73.323) | -68.141 (-75.721 to -60.561) | -67.784 (-79.273 to -56.294) | -0.550 (-9.307 to 8.207) |
| IgG2 | -75.346 (-84.395 to -66.297) | -53.678 (-62.077 to -45.280) | -53.879 (-65.648 to -42.110) | -0.481 (-9.392 to 8.431) |
| IgG3 | -88.260 (-98.901 to -77.619) | -65.211 (-74.336 to -56.085) | -66.182 (-79.856 to -52.508) | 0.503 (-9.907 to 10.914) |
| IgG4 | -68.559 (-77.456 to -59.663) | -55.391 (-63.131 to -47.651) | -52.916 (-64.774 to -41.059) | 0.163 (-9.167 to 9.493) |
Collected over From Baseline up to Week 20. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RVT-1401 680 mg/Week | 0/18 (0%) | 0/18 (0%) | 16/18 (88.9%) |
| RVT-1401 340 mg/Week | 0/19 (0%) | 0/19 (0%) | 16/19 (84.2%) |
| RVT-1401 255 mg/Week | 0/10 (0%) | 1/10 (10%) | 8/10 (80%) |
| Placebo | 0/18 (0%) | 0/18 (0%) | 16/18 (88.9%) |
| Event | RVT-1401 680 mg/Week | RVT-1401 340 mg/Week | RVT-1401 255 mg/Week | Placebo |
|---|---|---|---|---|
| Optic neuropathyEye disorders | 0/18 | 0/19 | 1/10 | 0/18 |
| Event | RVT-1401 680 mg/Week | RVT-1401 340 mg/Week | RVT-1401 255 mg/Week | Placebo |
|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 9/18 | 9/19 | 3/10 | 3/18 |
| Oedema peripheralGeneral disorders | 5/18 | 0/19 | 0/10 | 0/18 |
| LethargyNervous system disorders | 2/18 | 5/19 | 1/10 | 4/18 |
| NauseaGastrointestinal disorders | 0/18 | 4/19 | 0/10 | 2/18 |
| Injection site swellingGeneral disorders | 1/18 | 4/19 | 1/10 | 1/18 |
| Injection site painGeneral disorders | 1/18 | 3/19 | 0/10 | 0/18 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/18 | 3/19 | 0/10 | 0/18 |
| Intraocular pressure increasedInvestigations | 2/18 | 0/19 | 0/10 | 2/18 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/18 | 0/19 | 1/10 | 2/18 |
| Abdominal pain upperGastrointestinal disorders | 1/18 | 2/19 | 0/10 | 0/18 |
| Age, Continuous(Years) | RVT-1401 680 mg/Week | RVT-1401 340 mg/Week | RVT-1401 255 mg/Week | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 46.6 ± 9.03 | 52.4 ± 8.08 | 44.3 ± 12.61 | 46.1 ± 12.47 | 47.8 ± 10.64 |
| Sex: Female, Male(Participants) | RVT-1401 680 mg/Week | RVT-1401 340 mg/Week | RVT-1401 255 mg/Week | Placebo | Total |
|---|---|---|---|---|---|
| Female | 15 | 13 | 8 | 14 | 50 |
| Male | 3 | 6 | 2 | 4 | 15 |
| Ethnicity (NIH/OMB)(Participants) | RVT-1401 680 mg/Week | RVT-1401 340 mg/Week | RVT-1401 255 mg/Week | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 0 | 0 | 3 |
| Not Hispanic or Latino | 17 | 17 | 10 | 18 | 62 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | RVT-1401 680 mg/Week | RVT-1401 340 mg/Week | RVT-1401 255 mg/Week | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 17 | 18 | 10 | 18 | 63 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 2 |
| Mean Proptosis(Millimeters (mm)) | RVT-1401 680 mg/Week | RVT-1401 340 mg/Week | RVT-1401 255 mg/Week | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 22.7 ± 3.10 | 23.0 ± 3.97 | 22.3 ± 2.95 | 22.7 ± 2.70 | 22.72 ± 3.19 |
| Mean Clinical Activity Score (CAS)(Units on a scale) | RVT-1401 680 mg/Week | RVT-1401 340 mg/Week | RVT-1401 255 mg/Week | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 4.8 ± 0.86 | 5.1 ± 0.94 | 4.9 ± 0.99 | 5.2 ± 1.04 | 5.0 ± 0.94 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2019 to primary completion in Feb 2021, 18 months.
Results were first posted in Sep 2022, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HBM9161
Immunovant Sciences GmbH